MORRISVILLE, N.C.–(BUSINESS WIRE)–Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the first quarter of 2021 and provided a business update. “Having completed the merger with PHPrecisionMed […]
Other News
PhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology’s 70th Annual Scientific Session
Study leveraging the IBM® MarketScan® claims database examined bleeding events and rates of surgical procedures in patients initiating P2Y12 inhibitors, FXa inhibitors or dabigatran Analyses revealed that patients receiving P2Y12 inhibitors had a higher burden of significant comorbid conditions at baseline than patients receiving FXa inhibitors or dabigatran Results demonstrate patients prescribed P2Y12 inhibitors […]
ReCor Medical Announces Results from Landmark RADIANCE-HTN TRIO Study, Showing Clinically Significant Blood Pressure Reduction with the Paradise Ultrasound RDN System in Patients with Resistant Hypertension
PALO ALTO, Calif., May 16, 2021 /PRNewswire/ — ReCor Medical, Inc. (“ReCor”), a wholly-owned subsidiary of Otsuka Medical Devices Co., Ltd., today presented the primary endpoint data from the randomized sham-controlled RADIANCE-HTN TRIO (“TRIO”) study. In subjects with resistant hypertension, those treated with the Paradise™ Ultrasound Renal Denervation System had a greater drop in […]
Abbott Receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System to Treat Aortic Stenosis
– Latest-generation TAVI system features advancements to reduce or eliminate risk of blood leakage around valve implant – The non-surgical Navitor TAVI system offers best-in-class deliverability and access through small vessels, expanding treatment options for patients with severe aortic stenosis ABBOTT PARK, Ill., May 17, 2021 /PRNewswire/ — Abbott (NYSE: ABT) today announced it […]
New Meta-Analysis of Patients with Acute Coronary Syndrome Shows Nearly Half of Recurrent Major Adverse Cardiovascular Events at One Year Occur Within the First 90 Days
Findings signal need for novel treatment strategies to provide more protection during this high-risk, 90-day period KING OF PRUSSIA, Pa., May 16, 2021 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced the results of a new meta-analysis of seven interventional Phase 3 clinical trials that included more than 82,000 high-risk patients with […]
CardieX Launches CONNEQT™
New health tech company to compete with consumer tech giants Apple and Fitbit IRVINE, Calif., May 17, 2021 /PRNewswire/ — CardieX Limited (ASX: CDX), a global health technology company focused on hypertension, cardiovascular disease, and vascular health disorders, today announced CONNEQT™, a new consumer health company that will focus on home vital signs monitors, […]
Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update
MONTREAL and CHARLOTTE, N.C., May 17, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the first quarter ended March 31, 2021 and provided a clinical, regulatory, and corporate update. “We continue to work closely with our existing clinical trial sites, […]
REDUCE-IT® Heart Failure Analyses by VASCEPA® (Icosapent Ethyl)-Driven Serum Eicosapentaenoic Acid (EPA) Levels Suggest Potential Benefit in New Heart Failure in Studied At-Risk Patients as Presented at the American College of Cardiology’s 70th Annual Scientific Session
Post hoc analyses by estimated on-treatment serum EPA levels in the VASCEPA group suggest potentially reduced incidence of new heart failure and new heart failure requiring hospitalization with higher achieved serum EPA levels Amarin to Webcast Discussion of Data Presented at ACC.21 Monday, May 17, 2021 at 4:30 p.m., Eastern […]
Orchestra BioMed™ Announces Clinical Data Showing Significant and Sustained Reduction in Systolic Blood Pressure Out to Two Years with BackBeat Cardiac Neuromodulation Therapy™
Clinically meaningful and statistically significant reduction of 16.6 mmHg in systolic blood pressure out to two years 88% of the treated patients had isolated systolic hypertension (ISH) 70.6% of all treated patients and 80% of treated ISH patients had their blood pressure under control at 24 months NEW HOPE, Pa., […]
Cytokinetics Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 70th Annual Scientific Session and Published in the Journal of American College of Cardiology
Analysis Shows Treatment Effect of Omecamtiv Mecarbil Increased Progressively as Baseline Ejection Fraction Decreased SOUTH SAN FRANCISCO, Calif., May 17, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil on clinical outcomes in relationship […]



